Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • FROM THE ANALYST'S COUCH

Genomic medicines: the coming waves?

  1. Wen Xie

    1. Boston Consulting Group, Beijing, China. Present address: Millennium Management, New York, USA.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  2. Baiping Chen

    1. Boston Consulting Group, Beijing, China.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  3. John Wong

    1. Boston Consulting Group, Hong Kong, China.

    View author publications

    You can also search for this author in PubMed  Google Scholar

Genomic medicines have gone through periods of hype and disillusionment since their conceptualization. For example, the approval of the pioneering gene therapy alipogene tiparvovec (Glybera) a decade ago fuelled expectations of a subsequent wave of other virally delivered gene therapies. However, these expectations have not yet been realized, and with ~30 setbacks for genomic medicine candidates in the past 3 years (Supplementary Table 1), of which more than 50% were due to safety concerns, the valuation of public genomic medicine companies has fallen significantly (Supplementary Fig. 1). So, key questions for pharma companies and investors include how long will it take genomic medicines to realize their potential and how large will the associated markets be?

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Nature Reviews Drug Discovery 22, 691-692 (2023)

doi: https://doi.org/10.1038/d41573-023-00098-6

Supplementary Information

  1. Supplementary information

Competing Interests

J.W. and B.C. are employees of The Boston Consulting Group (BCG), a management consultancy that works with the world's leading biopharmaceutical companies. W.X. was an employee of BCG at the time the article was written. The research for this specific article was funded by BCG's healthcare practice and represents the views of BCG and does not represent the views of Millennium.

Nature Careers

Jobs

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing

Search

Advanced search

Quick links